Skip to main content
. 2022 Jun 16;12(5):671–681. doi: 10.21037/hbsn-21-546

Table 4. HRs of extrahepatic cancers in participants by MAFLD risk factors.

Cancer types One Two Three
Overweight-only DB-only MD-only Overweight and DB Overweight and MD DB and MD
Extrahepatic 0.91 (0.78–1.07) 0.52 (0.17–1.60) 1.42 (1.17–1.73) 1.23 (0.89–1.71) 1.04 (0.97–1.11) 1.36 (0.89–2.07) 1.05 (0.93–1.19)
Thyroid 1.97 (0.95–4.06) 0.78 (0.11–5.62) 2.26 (0.31–16.42) 1.45 (0.95–2.20) 1.25 (0.50–3.11)
Lung 0.92 (0.70–1.20) 1.00 (0.25–4.04) 1.26 (0.87–1.82) 1.45 (0.85–2.45) 0.93 (0.82–1.05) 0.59 (0.19–1.84) 0.78 (0.60–1.01)
Esophageal 0.53 (0.22–1.30) 4.37 (2.55–7.49) 0.75 (0.53–1.07) 1.46 (0.20–10.50) 0.86 (0.44–1.68)
Gastric 0.89 (0.51–1.55) 1.28 (0.60–2.70) 0.84 (0.21–3.38) 1.05 (0.83–1.33) 0.84 (0.12–6.05) 0.95 (0.59–1.53)
Biliary 1.51 (0.61–3.74) 0.70 (0.10–5.00) 1.72 (0.24–12.38) 0.69 (0.40–1.21) 1.37 (0.63–2.97)
Pancreatic 1.19 (0.52–2.73) 2.11 (0.78–5.73) 0.89 (0.58–1.36) 1.02 (0.48–2.21)
Small intestine 0.81 (0.11–5.91) 1.71 (0.85–3.43) 1.95 (0.58–6.51)
Colorectal 0.91 (0.59–1.40) 1.60 (0.96–2.68) 1.80 (0.85–3.80) 1.07 (0.89–1.29) 1.44 (0.46–4.46) 1.45 (1.07–1.96)
Kidney 1.16 (0.59–2.28) 0.79 (0.20–3.20) 0.87 (0.12–6.19) 1.83 (1.38–2.43) 1.02 (0.52–2.00)
Bladder 0.98 (0.46–2.09) 0.64 (0.16–2.61) 2.39 (0.76–7.51) 0.90 (0.63–1.28) 1.45 (0.20–10.40) 1.27 (0.72–2.23)
Prostate§ 0.51 (0.13–2.09) 1.22 (0.30–4.98) 1.37 (0.19–9.86) 1.46 (1.00–2.14) 2.44 (1.42–4.21)
Breast 0.83 (0.37–1.87) 1.99 (1.01–3.92) 1.46 (0.20–10.58) 1.33 (1.02–1.74) 2.65 (0.84–8.33) 1.17 (0.71–1.93)

Data were presented as HR (95% confidence interval). The model was adjusted for age, sex, education level, smoking status, alcohol consumption, physical activity, and family history of cancers. §, only for men; , only for women; –, no cancer was observed in this group. HR, hazards ratio; MAFLD, metabolic dysfunction-associated fatty liver disease; DB, diabetes; MD, metabolic dysregulation.